Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/17930
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BOSETTI, Rita | - |
dc.contributor.author | Ferrandina, Gabriella | - |
dc.contributor.author | MARNEFFE, Wim | - |
dc.contributor.author | Scambia, Giovanni | - |
dc.contributor.author | VEREECK, Lode | - |
dc.date.accessioned | 2014-12-05T13:14:34Z | - |
dc.date.available | 2014-12-05T13:14:34Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | NANOMEDICINE, 9 (14), p. 2175-2186 | - |
dc.identifier.issn | 1743-5889 | - |
dc.identifier.uri | http://hdl.handle.net/1942/17930 | - |
dc.description.abstract | This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer. | - |
dc.language.iso | en | - |
dc.subject.other | PEGylated liposomal doxorubicin; chemotherapy; cost–effectiveness; gemcitabine; nanotherapy; ovarian cancer; quality of life | - |
dc.title | Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 2186 | - |
dc.identifier.issue | 14 | - |
dc.identifier.spage | 2175 | - |
dc.identifier.volume | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Bosetti, R (reprint author), Hasselt Univ, Dept Appl Econ, Martelarenlaan 42 BE3500, Hasselt, Belgium. rita.bosetti@uhasselt.be | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.2217/nnm.14.150 | - |
dc.identifier.isi | 000345285700010 | - |
dc.identifier.url | http://www.ncbi.nlm.nih.gov/pubmed/25405795 | - |
item.contributor | BOSETTI, Rita | - |
item.contributor | Ferrandina, Gabriella | - |
item.contributor | MARNEFFE, Wim | - |
item.contributor | Scambia, Giovanni | - |
item.contributor | VEREECK, Lode | - |
item.fullcitation | BOSETTI, Rita; Ferrandina, Gabriella; MARNEFFE, Wim; Scambia, Giovanni & VEREECK, Lode (2014) Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy. In: NANOMEDICINE, 9 (14), p. 2175-2186. | - |
item.accessRights | Closed Access | - |
item.fulltext | No Fulltext | - |
item.validation | ecoom 2015 | - |
crisitem.journal.issn | 1743-5889 | - |
crisitem.journal.eissn | 1748-6963 | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
6
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
7
checked on Apr 30, 2024
Page view(s)
56
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.